Short interest screen · refreshed after the Sep 28, 2026 close
Short squeeze monitor: Healthcare
Stocks with the largest share of their tradable float sold short. A high share of float sold short means many traders are betting on a decline. If the price rises instead, short sellers may need to buy shares to close their positions, which can add to the move. Days to cover shows how many average trading days that buying would take.
| # | Company | Price | Today | Short % float | Days to cover | Δ short int. | Short vol. 10d | Mkt cap |
|---|---|---|---|---|---|---|---|---|
| 1 | LENZLENZ TherapeuticsHealthcare | $3.96 | +1.15% | 75.5% | 14.6 | −2% | 55.1% | $124.4M |
| 2 | SRZNSurrozenHealthcare | $29.64 | +0.34% | 53.5% | 12.7 | +52% | 62.7% | $348.4M |
| 3 | CAPRCapricor TherapeuticsHealthcare | $8.71 | +4.19% | 48.0% | 5.9 | −11% | 38.5% | $506.4M |
| 4 | MMEDMiniMed GroupHealthcare | $20.49 | +2.55% | 47.8% | 4.9 | +69% | 66.1% | $5.76B |
| 5 | SPRYARS PharmaceuticalsHealthcare | $4.13 | +1.23% | 47.1% | 15.5 | −1% | 57.7% | $410.7M |
| 6 | COAGHemab Therapeutics HoldingsHealthcare | $33.12 | −4.66% | 41.7% | 7.5 | +25% | 74.5% | $1.55B |
| 7 | RXRXRecursion PharmaceuticalsHealthcare | $3.70 | −1.07% | 41.4% | 12.6 | 0% | 56.9% | $1.98B |
| 8 | CCCCC4 TherapeuticsHealthcare | $3.12 | +4.53% | 40.8% | 22.7 | +7% | 38.2% | $383.2M |
| 9 | NTLAIntellia TherapeuticsHealthcare | $11.42 | −2.81% | 40.7% | 14.1 | +6% | 55.6% | $1.60B |
| 10 | GLUEMonte Rosa TherapeuticsHealthcare | $11.71 | −0.51% | 39.1% | 17.1 | +7% | 55.5% | $999.0M |
| 11 | ZBIOZenas BioPharmaHealthcare | $27.55 | +2.23% | 38.1% | 22.4 | +1% | 67.1% | $1.80B |
| 12 | BBNXBeta BionicsHealthcare | $20.52 | −4.60% | 37.4% | 9.9 | +13% | 50.8% | $1.11B |
| 13 | INBXInhibrx BiosciencesHealthcare | $101.71 | +2.11% | 36.5% | 8.3 | +3% | 65.5% | $1.50B |
| 14 | SGMTSagimet Biosciences Inc. Series AHealthcare | $9.94 | +7.58% | 36.3% | 10.6 | +1% | 50.7% | $617.9M |
| 15 | REPLReplimune GroupHealthcare | $12.56 | +1.62% | 36.1% | 11.1 | −3% | 60.4% | $1.18B |
| 16 | KODKodiak SciencesHealthcare | $89.92 | +177.96% | 34.2% | 17.9 | −1% | 61.6% | $5.65B |
| 17 | PRMEPrime MedicineHealthcare | $2.88 | −0.86% | 33.6% | 12.3 | −13% | 57.8% | $521.5M |
| 18 | ABEOAbeona TherapeuticsHealthcare | $5.29 | −2.04% | 33.2% | 12.0 | +4% | 62.1% | $302.5M |
| 19 | NVAXNovavaxHealthcare | $10.80 | +1.60% | 31.9% | 9.3 | +2% | 49.8% | $1.78B |
| 20 | IBRXImmunityBioHealthcare | $8.52 | +0.95% | 31.7% | 15.9 | 0% | 54.6% | $9.03B |
| 21 | BEAMBeam TherapeuticsHealthcare | $24.23 | −0.16% | 31.6% | 12.6 | 0% | 74.0% | $2.50B |
| 22 | NRXPNRX PharmaceuticalsHealthcare | $2.87 | −4.17% | 31.5% | 16.3 | +5% | 40.8% | $124.3M |
| 23 | WGSGeneDx HoldingsHealthcare | $85.93 | −2.79% | 31.3% | 12.1 | −2% | 59.7% | $2.56B |
| 24 | ANABAnaptysBioHealthcare | $50.80 | −0.39% | 31.1% | 10.3 | 0% | 45.6% | $1.52B |
| 25 | QTTBQ32 BioHealthcare | $9.23 | +5.25% | 30.6% | 5.2 | +6% | 62.1% | $274.8M |
| 26 | SMMTSummit TherapeuticsHealthcare | $15.48 | −0.83% | 29.9% | 6.6 | −1% | 61.3% | $12.35B |
| 27 | TNGXTango TherapeuticsHealthcare | $24.30 | −2.49% | 29.8% | 18.8 | −2% | 53.2% | $4.10B |
| 28 | SLSSELLAS Life Sciences GroupHealthcare | $11.59 | −0.17% | 29.6% | 8.6 | +2% | 60.7% | $2.34B |
| 29 | SVRASavaraHealthcare | $5.07 | +1.40% | 29.6% | 36.3 | +5% | 60.9% | $1.04B |
| 30 | NEGGNewegg CommerceHealthcare | $13.04 | −3.55% | 29.6% | 4.0 | −15% | 51.4% | $273.5M |
| 31 | TYRATyra BiosciencesHealthcare | $21.45 | −1.42% | 29.5% | 5.7 | +5% | 79.5% | $1.47B |
| 32 | CELCCelcuityHealthcare | $79.64 | +0.15% | 28.5% | 12.5 | +6% | 61.3% | $3.90B |
| 33 | LXEOLexeo TherapeuticsHealthcare | $3.14 | −5.14% | 28.2% | 33.4 | +1% | 50.4% | $257.8M |
| 34 | ALTAltimmuneHealthcare | $2.96 | −3.27% | 28.1% | 15.4 | +4% | 49.5% | $575.8M |
| 35 | AVBPArriVent BioPharmaHealthcare | $29.30 | +2.99% | 28.0% | 17.7 | +1% | 61.5% | $1.44B |
| 36 | OLMAOlema PharmaceuticalsHealthcare | $8.61 | −1.60% | 27.8% | 15.9 | +3% | 55.4% | $753.4M |
| 37 | IMRXImmuneeringHealthcare | $4.16 | −2.58% | 27.8% | 20.6 | +5% | 58.5% | $269.1M |
| 38 | ORICOric PharmaceuticalsHealthcare | $13.27 | +0.84% | 27.3% | 14.2 | +2% | 63.3% | $1.38B |
| 39 | HIMSHims & Hers HealthHealthcare | $28.78 | −2.18% | 27.2% | 6.1 | −4% | 64.8% | $6.71B |
| 40 | FDMT4D Molecular TherapeuticsHealthcare | $14.56 | +0.62% | 27.0% | 18.6 | −1% | 57.6% | $804.4M |
| 41 | VERAVera TherapeuticsHealthcare | $32.50 | −0.12% | 26.9% | 6.2 | −14% | 59.5% | $2.34B |
| 42 | OPTXSyntec Optics HoldingsHealthcare | $7.09 | −4.19% | 26.6% | 7.9 | −13% | 58.0% | $285.6M |
| 43 | JBIOJade BiosciencesHealthcare | $14.35 | −0.49% | 26.6% | 11.8 | +10% | 49.3% | $912.6M |
| 44 | RLAYRelay TherapeuticsHealthcare | $17.69 | +1.26% | 26.2% | 14.2 | +2% | 71.0% | $3.88B |
| 45 | SRPTSarepta Therapeutics,Healthcare | $18.80 | +0.70% | 25.9% | 8.0 | +3% | 62.1% | $1.99B |
| 46 | GLSIGreenwich LifeSciencesHealthcare | $18.59 | +2.03% | 25.7% | 19.8 | −2% | 57.5% | $272.9M |
| 47 | NGNENeurogeneHealthcare | $28.48 | +0.60% | 25.5% | 16.9 | +5% | 71.2% | $569.9M |
| 48 | SIONSionna TherapeuticsHealthcare | $5.12 | −2.10% | 25.4% | 3.1 | −8% | 42.6% | $231.5M |
| 49 | ACHVAchieve Life SciencesHealthcare | $7.75 | +2.79% | 25.2% | 9.1 | −3% | 60.0% | $797.5M |
| 50 | AQSTAquestive TherapeuticsHealthcare | $4.75 | +1.50% | 25.2% | 11.8 | +7% | 49.1% | $596.2M |
Data guard: 9 stocks withheld — NG (reported short interest is above 100% of float); EGO (reported short interest is above 100% of float); BNS (reported short interest is above 100% of float); AQN (reported short interest is above 100% of float); CAE (reported short interest is above 100% of float); GIL (reported short interest is above 100% of float); EPRX (reported short interest is above 100% of float); MFI (reported short interest is above 100% of float); CHRN (float record is implausibly small). They return once the float record is verified.
Method & sources
Computed after each close from Massive / Polygon prices (split-adjusted), SEC filings, FINRA short-interest settlements and FMP earnings dates. Rows are rebuilt every session; a stock appears only when every criterion is met with current data. Full methodology
Informational screen, not a recommendation.